

Results of General Meeting

Paradigm Biopharmaceuticals Ltd (ASX:PAR) (“Paradigm” or “the Company”), a late-stage drug development company focused on delivering new therapies to address unmet medical needs, advises the outcomes of the General Meeting held on 29 May 2025.

The results of each resolution are as follows:

Resolution	For	For (%)	Against	Against (%)	Total Votes Cast	Outcome
1 – Ratification of Placement Shares	68,810,808	95.50%	3,236,849	4.5%	72,047,657	Carried
2 – Amendment to Constitution	75,447,458	64.89%	40,829,376	35.11%	116,276,834	Not Carried (Required 75%)

All discretionary proxies were directed to vote in favour of each resolution.

Based on shareholder feedback following the outcome of Resolution 2, which did not carry, Paradigm would like to clarify its intention regarding the proposed constitutional amendment allowing for virtual-only meetings as a part of the amendment.

The Company confirms that:

- Shareholders would retain the same rights in virtual meetings as they would in physical or hybrid meetings. This includes the ability to vote, ask questions, and participate fully in meeting proceedings in accordance with the Corporations Act and ASX Listing Rules.
- The amendment was proposed to provide flexibility where a physical or hybrid meeting may not be feasible (for example, travel restrictions, public health orders, or emergencies).
- It is the Company’s intention to continue holding Annual General Meetings (AGMs) in a hybrid format, thereby retaining an in-person attendance option for shareholders while enabling broader access through remote participation.

The Paradigm Board would like to thank all shareholders for voting and those that were able to attend the in-person meeting today.

-Ends-

About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Ltd. (ASX: PAR) is a late-stage drug development company driven by a purpose to improve patients’ health and quality of life by discovering, developing, and delivering pharmaceutical therapies. Paradigm’s current focus is developing iPPS for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative

properties of PPS, such as in osteoarthritis (phase 3) and mucopolysaccharidosis (phase 2).

To learn more please visit: <https://paradigmbiopharma.com>

Approved for release by the Paradigm Board of Directors.

FOR FURTHER INFORMATION PLEASE CONTACT:

Simon White

Director of Investor Relations

Tel: +61 404 216 467

Paradigm Biopharmaceuticals Ltd

ABN: 94 169 346 963

Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA

Email: investorrelations@paradigmbiopharma.com